Presumptive Amphetamine Urine Screens: What a Positive Immunoassay Does and Does Not Prove
Published by THE OKOROCHA FIRM*. Read the full Content Disclaimer.
The short answer
A positive urine amphetamine immunoassay is a presumptive screening result. By itself, it does not identify the exact substance that produced the response, establish whether the substance was d- or l-methamphetamine, prove when exposure occurred, quantify a dose, or demonstrate impairment at a particular time.
Before a high-consequence decision is made, the record should identify the assay, cutoff, specimen-validity information, medication and exposure history, and the result of an independent confirmatory method. When methamphetamine source matters, ordinary mass-spectrometric confirmation may still be incomplete unless the laboratory used a validated enantiomer-specific method.
Why the word “presumptive” matters
Immunoassays use antibodies to recognize a target drug or drug class. They are useful because they are fast, relatively inexpensive, and adaptable to high-volume testing. The same antibody response that makes screening efficient can also respond to a non-target compound whose structure is sufficiently similar to the assay target.
The practical consequence is not that every positive screen is wrong. It is that the screen answers a limited question: did this specimen produce a response at or above the assay’s decision threshold? It does not, without more, establish the identity and source of the responding compound.
Saitman, Park, and Fitzgerald reviewed reported interferences across common urine drug-screen immunoassays and explained that positive immunoassay results should be treated as presumptive until confirmed by a second, independent chemical technique. Their review also shows why a generic list of “false-positive medications” is not enough. Cross-reactivity depends on the particular assay, antibody design, cutoff, compound concentration, and sometimes the compound’s metabolites.
Screening and confirmation answer different questions
An immunoassay screen and a chromatographic mass-spectrometric confirmation are not interchangeable labels for the same test.
The screen generally reports a class-level response above or below a cutoff. Confirmation by gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry is designed to separate compounds and identify specified analytes using more selective criteria. A confirmatory panel, however, detects only the compounds and metabolites included in the method and only at or above its reporting limits.
That distinction produces several possible patterns:
1. A presumptive positive screen followed by confirmation of amphetamine or methamphetamine.
2. A presumptive positive screen followed by a negative confirmation because a cross-reacting non-target compound produced the screen response.
3. A positive screen followed by a negative targeted confirmation because the substance present was not included in the confirmation panel.
4. A negative screen despite a drug or metabolite being present below the screening cutoff, outside the antibody’s useful cross-reactivity, or after the relevant detection window.
Reisfield, Goldberger, and Bertholf cautioned that the terms “false positive” and “false negative” can themselves create confusion. Laboratory professionals may use those terms in relation to an analyte and cutoff, while clinicians may use them in relation to a patient’s behavior. A sound interpretation states the analyte, method, cutoff, and question being answered.
Medication and supplement review must be assay-specific
A medication list should be collected before the result is interpreted, but the analysis should not stop at finding a medication somewhere on an internet list. The more defensible sequence is:
identify the manufacturer, platform, reagent, and assay version;
obtain the package insert and its cross-reactivity data;
determine the screening cutoff and the observed response;
compare the timing and expected urinary concentration of the proposed interferent;
evaluate metabolites, not only the parent medication;
review the scope and sensitivity of the confirmation method; and
consult the laboratory when the result is unexpected or consequential.
Brahm and colleagues reviewed reports involving routinely prescribed and nonprescription medications. Amphetamine and methamphetamine screens were the most commonly reported category in that review, but the authors recommended verification with a different or additional analytical method to avoid adverse consequences. The existence of a published association is a reason to investigate. It is not automatic proof that a particular medication caused a particular patient’s result.
A documented example: DMAA
Dimethylamylamine, also called DMAA in the literature, illustrates why confirmation scope matters. Vorce and colleagues investigated specimens that screened positive on two amphetamine immunoassays but did not confirm for amphetamines by the laboratory’s GC-MS method. They analyzed 134 additional false-positive specimens using LC-MS/MS and detected DMAA in 92.3 percent of them.
This study does not mean DMAA explains every unconfirmed amphetamine screen. It demonstrates a narrower and more important point: a compound not identified by the routine amphetamine confirmation can account for a reproducible immunoassay response, and an investigation may require a method specifically capable of detecting that compound.
A controlled example: l-methamphetamine in a nasal inhaler
Methamphetamine has stereoisomers, commonly described as d- and l-methamphetamine. They share the same molecular formula but differ in three-dimensional arrangement and pharmacologic effect. A non-chiral confirmation identifies total methamphetamine but does not necessarily establish which enantiomer is present.
Smith and colleagues enrolled 22 healthy adults in a controlled Vicks VapoInhaler study; 17 completed the dosing and specimen-collection protocol. The inhaler contained l-methamphetamine. Enantiomer-specific GC-MS detected no d-methamphetamine or d-amphetamine in any specimen. Among the 17 participants who completed the protocol, the median peak l-methamphetamine concentration was 62.8 micrograms per liter, with a range of 11.0 to 1,440 micrograms per liter.
The three evaluated amphetamine immunoassays did not perform identically. The reported specificities were 97.8 percent for EMIT II Plus, 99.6 percent for KIMS II, and 100 percent for DRI in the tested specimen sets. EMIT II Plus produced a 2.2 percent false-positive rate under the study definition. The study therefore supports two careful conclusions: modern assays can perform well overall, and assay-specific false-positive responses can still occur after a legitimate l-methamphetamine exposure.
When a confirmed methamphetamine result may have a legitimate source, an enantiomer-specific analysis can be critical. The laboratory report should state whether the method separated d- and l-methamphetamine and should report the applicable measurement uncertainty, cutoff, and interpretive criteria.
What a urine result cannot establish by itself
Even a properly confirmed urine result has boundaries. Urine primarily reflects excretion. Concentration can vary with hydration, urine pH, renal handling, time since exposure, repeated dosing, metabolism, and the interval represented by the bladder contents.
A urine result alone ordinarily cannot establish:
the exact time a drug was taken;
the exact dose;
the route of administration;
impairment at the time of driving, an incident, examination, or workplace event;
whether observed signs were caused by the detected drug;
whether a positive result represents a prescribed, over-the-counter, environmental, or illicit source; or
whether a negative result proves no prior exposure.
Those questions require integration of the analytical record with collection timing, specimen validity, medical and medication history, observed behavior, pharmacology, and the limitations of the specific method.
Records needed for an independent review
A meaningful review usually requires more than the one-page result summary. Depending on the setting, useful records can include:
chain-of-custody and specimen-identification records;
collection date and time;
specimen-validity results, including creatinine, specific gravity, pH, and oxidant testing when performed;
assay manufacturer, platform, reagent lot, calibration, controls, cutoff, and package insert;
the raw screening response when retained;
confirmation method, analyte list, reporting limits, calibrators, controls, chromatograms, ion ratios, retention times, and integration records;
dilution, repeat-testing, rerun, and amended-report history;
medication, nonprescription product, supplement, and inhaler history;
laboratory standard operating procedures and applicable accreditation requirements; and
enantiomer-specific data when methamphetamine source is disputed.
A defensible interpretation checklist
1. Define the result precisely
Was the reported finding only a presumptive class screen, or was a named analyte confirmed? What cutoff and reporting limit applied?
2. Identify the exact method
Which assay and reagent version produced the screen? Which compounds were included in confirmation? Was the confirmation chiral or non-chiral?
3. Review plausible exposures
Evaluate prescriptions, over-the-counter products, supplements, and metabolites against assay-specific evidence. Do not assume that every published interferent applies to every platform.
4. Check specimen and process integrity
Confirm identity, custody, timing, storage, validity testing, controls, and whether repeats or amendments occurred.
5. Match the conclusion to the evidence
Do not convert detection into a claim about dose, timing, source, behavior, or impairment unless independent evidence supports that additional conclusion.
Frequently asked questions
Does a positive amphetamine immunoassay prove methamphetamine use?
No. It is a presumptive class-screen response. Identification of methamphetamine requires an appropriately selective confirmation method, and source attribution may require enantiomer-specific testing.
Can prescribed or over-the-counter products affect an amphetamine screen?
Yes, some medications, metabolites, supplements, and products have produced assay-dependent cross-reactivity. The exact assay and confirmation record must be reviewed before attributing a result to an interferent.
Is GC-MS confirmation always enough to distinguish legal and illicit methamphetamine sources?
No. Ordinary GC-MS can confirm methamphetamine without distinguishing d- from l-methamphetamine. A validated chiral or enantiomer-specific method may be needed when stereoisomer source is material.
Can a urine concentration prove impairment?
Not by itself. Urine concentration is affected by excretion and specimen conditions and is not a direct measurement of contemporaneous central nervous system effect.
What should happen before an adverse decision is made?
The presumptive result should be evaluated against confirmation data, the exact assay and cutoff, specimen validity, relevant exposures, and the question the testing program is authorized to answer.
Related reading
For additional context, review urine drug testing fundamentals, common drug-testing myths, and the role of a forensic toxicologist as an expert witness.
Sources
1. Reisfield GM, Goldberger BA, Bertholf RL. “False-positive” and “false-negative” test results in clinical urine drug testing. Bioanalysis. 2009;1(5):937-952. doi:10.4155/bio.09.81.
2. Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. American Journal of Health-System Pharmacy. 2010;67(16):1344-1350. doi:10.2146/ajhp090477.
3. Vorce SP, Holler JM, Cawrse BM, Magluilo J Jr. Dimethylamylamine: a drug causing positive immunoassay results for amphetamines. Journal of Analytical Toxicology. 2011;35(3):183-187. doi:10.1093/anatox/35.3.183.
4. Saitman A, Park HD, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: a review. Journal of Analytical Toxicology. 2014;38(7):387-396. doi:10.1093/jat/bku075.
5. Smith ML, Nichols DC, Underwood P, et al. Methamphetamine and amphetamine isomer concentrations in human urine following controlled Vicks VapoInhaler administration. Journal of Analytical Toxicology. 2014;38(8):524-527. doi:10.1093/jat/bku077.
This educational article is not legal or medical advice. Interpretation depends on the complete record, the testing purpose, and the methods actually used.
